WO2006001965A3 - Reducing the risk of human anti-human antibodies through v gene manipulation - Google Patents

Reducing the risk of human anti-human antibodies through v gene manipulation Download PDF

Info

Publication number
WO2006001965A3
WO2006001965A3 PCT/US2005/018143 US2005018143W WO2006001965A3 WO 2006001965 A3 WO2006001965 A3 WO 2006001965A3 US 2005018143 W US2005018143 W US 2005018143W WO 2006001965 A3 WO2006001965 A3 WO 2006001965A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
methods
haha
risk
reducing
Prior art date
Application number
PCT/US2005/018143
Other languages
French (fr)
Other versions
WO2006001965A2 (en
Inventor
Sirid-Aimee Kellermann
Larry L Green
Wouter Korver
Original Assignee
Abgenix Inc
Sirid-Aimee Kellermann
Larry L Green
Wouter Korver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/009306 external-priority patent/WO2005092926A2/en
Application filed by Abgenix Inc, Sirid-Aimee Kellermann, Larry L Green, Wouter Korver filed Critical Abgenix Inc
Publication of WO2006001965A2 publication Critical patent/WO2006001965A2/en
Publication of WO2006001965A3 publication Critical patent/WO2006001965A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Abstract

The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.
PCT/US2005/018143 2004-05-24 2005-05-23 Reducing the risk of human anti-human antibodies through v gene manipulation WO2006001965A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US57466104P 2004-05-24 2004-05-24
US60/574,661 2004-05-24
USPCT/US2005/009306 2005-03-17
PCT/US2005/009306 WO2005092926A2 (en) 2004-03-19 2005-03-17 Reducing the risk of human and anti-human antibodies through v gene manipulation
US11/084,554 2005-03-17
US11/084,554 US20050260679A1 (en) 2004-03-19 2005-03-17 Reducing the risk of human anti-human antibodies through V gene manipulation

Publications (2)

Publication Number Publication Date
WO2006001965A2 WO2006001965A2 (en) 2006-01-05
WO2006001965A3 true WO2006001965A3 (en) 2006-07-20

Family

ID=35431989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018143 WO2006001965A2 (en) 2004-05-24 2005-05-23 Reducing the risk of human anti-human antibodies through v gene manipulation

Country Status (1)

Country Link
WO (1) WO2006001965A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
JP5689816B2 (en) 2009-01-09 2015-03-25 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド Parenteral pharmaceutical composition and method for producing the parenteral pharmaceutical composition
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
EP2914625A2 (en) 2012-11-01 2015-09-09 AbbVie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LOTZE AND THOMSON: "Measuring immunity: basic biology and clinical medicine", December 2005, ELSEVIER, XP008058931 *
SA KELLERMANN, L. ROSKOS, R. FAGGIONI, LL GREEN: "Developping the Xenomouse technology for evaluating immunogenicity", XP002364353, Retrieved from the Internet <URL:http://diagnosticscrc.org/publications/brochures/AntibOZ-2.pdf> [retrieved on 20040323] *

Also Published As

Publication number Publication date
WO2006001965A2 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
WO2005092926A3 (en) Reducing the risk of human and anti-human antibodies through v gene manipulation
WO2006001965A3 (en) Reducing the risk of human anti-human antibodies through v gene manipulation
EP2025749B8 (en) Humanized anti-human osteopontin antibody
WO2005047307A3 (en) Il-18 binding proteins
WO2005047860A3 (en) Antibodies to alpha-synuclein
WO2003068801A3 (en) Antibody variants with faster antigen association rates
WO2005026211A3 (en) Anti-ghrelin antibodies
WO2009036209A3 (en) Homogeneous antibody populations
BRPI0611714A2 (en) il-12 / p40 binding proteins
WO2008079359A3 (en) Human antibodies that bind human il-12 and methods for producing
WO2008082651A3 (en) Dual-specific il-1a/ il-1b antibodies
IL179102A0 (en) HUMANIZED Fc??RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL180152A0 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
HK1081647A1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
WO2003033670A3 (en) Method for preparation of single chain antibodies
WO2008101177A3 (en) Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis
WO2002075274A3 (en) Method and kit for following neurodegenerative diseases
WO2004025248A3 (en) Antibody pair screening methods
EP1915176A4 (en) Highly sensitive immunoassays and antibodies for detection of blood factor viii
WO2008146165A3 (en) Kit of parts for the treatment of cancer or infectious diseases
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
WO2005016951A3 (en) Anti-ghrelin fab antibodies
IL164011A0 (en) Antagonistic anti-hfas ligand human antibodies andfragments thereof
WO2005116652A3 (en) Method for in vitro diagnosis of sjörgen’s syndrome and lupus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 160.1 EPC

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 05785679

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 05785679

Country of ref document: EP

Kind code of ref document: A2